Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction

Abstract

To determine the effect of dexamethasone when treating malignant bowel obstruction, 35 patients were randomized to receive intravenous dexamethasone or a placebo, crossing over to the alternate treatment arm if there had been no resolution of obstruction by day 5. This was done in two consecutive studies. Patients were stratified according to whether or not they had received specific anticancer therapy within 28 days of study. In trial 1, 15 out of 22 patients ‘responded’ (resolution of obstruction by day 5; 10 on dexamethasone, five on placebo). Eleven out of 15 patients were ‘on treatment’. In trial 2, six out of 13 responded (three on dexamethasone, three on placebo); three out of six were ‘on treatment’. When both studies are combined, 60% (21/35) patients responded (13 on dexamethasone, eight on placebo). Poor patient accrual terminated both studies. Numbers are too small to allow a combination of studies or formal statistical analysis. We are unable to make any conclusion as to the effectiveness of dexamethasone in the palliation of malignant bowel disease.

Keywords

controlled clinical trials dexamethasone intestinal obstruction palliative care

References

Baines M , Oliver DJ , Carter RL . Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet 1985; 2: 990–993.

Chan A , Woodruff RK . Intestinal obstruction inpatients with widespread intra-abdominal malignancy. J Pain Symptom Manage 1992; 7: 339–342.

Fainsinger RL , Spachynzki K , Hanson J , Bruera E . Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage 1994; 9: 12–18.

Ripamonti C . Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 1994; 9: 193–200.

Reid DB . Palliative management of bowel obstruction. Med J Aust 1988; 148: 54.

Baines M . The pathophysiology and management of malignant intestinal obstruction. In: Doyle D , Hanks G , MacDonald N eds. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993: 311–316.

Twycross R . Corticosteroids in advanced cancer. Br Med J 1992; 305: 969–970.

Eddy DM . Three battles to watch in the 1990s. J Am Med Assoc 1993; 270: 520–526.

Heidmal K , Hirschberg H , Slettebo H , Watne K , Nome O . High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neuro-oncol 1992; 12: 141–144.

10.

Bruera E , Roca E , Cedaro L , Carraro S , Chacon R . Action of oral methyl prednisolone in terminal cancer patients: a prospective randomised double-blind study. Cancer Treat Rep 1985; 69: 751–754.

11.

Popiela T , Lucchi R , Giongo F . Methylprednisolone as palliative therapy for female terminal cancer patients. Br J Cancer Clin Oncol 1989; 25: 1823–1829.

12.

Bodsch W , Rommel T , Ophoff B G , Menzel J . Factors responsible for retention of fluid in human tumour oedema and the effect of dexamethasone. J Neurosurg 1987; 67: 250–257.

13.

Koehler PJ . Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995; 6: 19–33.

14.

Ahmedzai S . Palliation of respiratory symptoms. In: Doyle D , Hanks G , MacDonald N eds. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993: 311–316.

15.

Piver MS , Barlow JJ , Shashikant B , Lele MD , Frank A . Survival after ovarian cancer induced intestinal obstruction. Gynecol Oncol 1982; 13: 44–49.

16.

Mercadante S , Spoldi E , Caraceni A , Maddaloni S , Simonetti MT . Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 7: 295–299.

17.

Khoo D , Hall E , Motson R , Riley J , Denman K , Waxman J . Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer Care 1994; 30: 28–30.